Released Aug 13, 2024, before the open
10-Q filed Aug 13, 2024, 44 days after period end · 0001576885-24-000092
Q2 2024 · 10-Q
Revenue—
Net Income-$20.54M-$20.54M N/M vs Q2 2023N/M vs Q1 2024
EPS Diluted-$0.34-$0.34 N/M vs Q2 2023N/M vs Q1 2024
Operating Income-$24,381,000N/M
Operating Cash Flowderived-$16,545,000N/M
Free Cash Flowderived-$16,550,000N/M
What the release said
The release
Same quarter
| Metric | Q2 2024 | Q2 2023 | Q2 2022 | Q2 2021 |
|---|---|---|---|---|
| Net Income | -$20.54M | -$11.61M | -$10.15M | -$61.36M |
| EPS Diluted | -$0.34 | -$0.28 | -$0.25 | -$141.93 |
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Acumen Pharmaceuticals, Inc. · CIK 1576885 · Engraved from SEC EDGAR